Jacobs Solutions reported Q2 FY24 results with revenue up 4.7% Y/Y, beating consensus. They also narrowed their outlook for adjusted EBITDA and EPS. Stock trading lower.
Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024 revenue guidance: $225-$245 million.
Rockwell Automation reported lower Q2 FY24 results and cut its FY24 outlook. Sales fell 6.6% Y/Y, but total ARR grew 20% Y/Y. Adjusted EPS beat estimates at $2.50. Company is searching for new CFO.
Lucid reported first-quarter revenue of $172.8 million, which beat the consensus estimate of $156.99 million, according to Benzinga Pro. The EV maker reported an adjusted loss of 30 cents per share, which missed estimates for a loss of 25 cents per share.
Palantir said first-quarter revenue increased 21% year-over-year to $634 million, which beat the consensus estimate of $625.431 million, according to Benzinga Pro. Palantir reported adjusted earnings of 8 cents per share, which was in line with analyst estimates. The company has now delivered six straight quarters of GAAP profitability.